NexImmune, Inc. Alternatives & Competitors

12 companies similar to NexImmune, Inc. — NexImmune, Directing T cell function to restore natural immunity

Arcellx

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

224 Acquired $8.43B

Redwood City, United Stat...

Biopharma Biotechnology +3

Marker Therapeutics, Inc.

Pioneering a Multi-Antigen Approach

20 Grant $98.60M

Houston, United States

Biotechnology Health and Wellness

Apexigen

Creating Transformative Immunotherapies for Patients with Cancer

11 Post-IPO Equity $175.80M

San Carlos, United States

Biopharma Biotechnology +2

Trillium Therapeutics Inc.

Clinical stage immuno-oncology company developing innovative therapies for the treatment o...

14 Post-IPO Equity $281.98M

Cambridge, United States

Biopharma Biotechnology +1

Track all NexImmune, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Simcha Therapeutics

Overcoming biological challenges in clinically translatable pathways.

15 Series B $65.00M

New Haven, United States

Biotechnology Health and Wellness +2

Georgiamune Inc.

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...

30 Series A $75.00M

Gaithersburg, United Stat...

Biotechnology Health Care +1

Cantargia AB

A Swedish listed biotechnology company

32 Post-IPO Equity $257.00M

Lund, Sweden

Biotechnology Health and Wellness +1

OncoResponse

Interrogating for Cures

10 $117.10M

Houston, United States

Biopharma Biotechnology +2

Macomics

Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to c...

24 Series A $7.44M

Edinburgh, United Kingdom

Biotechnology Health and Wellness +1

Compass Therapeutics Inc.

We are developing next-generation antibodies into transformative cancer therapies that imp...

57 IPO $500.96M

Boston, United States

Biopharma Biotechnology +1

ImmunoGenesis, Inc.

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mech...

14 Venture round $28.00M

Houston, United States

Biotechnology Health Care +2

AnaptysBio

Transforming patient health by delivering innovative immunology therapeutics.

144 IPO $185.90M

San Diego, United States

Biotechnology Health Care +1

About NexImmune, Inc.

NexImmune, Inc. is a publicly traded, clinical stage biotechnology company founded in 2011 and is making strides in the development of T cell immunotherapies through its propriety Artificial Immune Modulation (AIM™) technology. The company is focused on addressing unmet medical needs in oncology, specifically targeting...

Taxonomy

Immunotherapy, T Cell Immunotherapies, Cancer Treatment, Clinical Stage, Proprietary Technology, AIM Technology, Oncology, Autoimmune Disorders, Pharmaceutical Company, Immuno-therapeutics, Artificial Immune Modulation, Nanoparticles, Acute Myeloid Leukemia, Multiple Myeloma

Frequently Asked Questions

Companies similar to NexImmune, Inc. include Arcellx, Marker Therapeutics, Inc., Apexigen, Trillium Therapeutics Inc., Simcha Therapeutics. They work in Biotechnology and Health and Wellness and share NexImmune, Inc.'s focus on immunotherapy, cancer treatment and acute myeloid leukemia.

Bounce Watch lists 12 companies that share NexImmune, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches NexImmune, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

NexImmune, Inc. Profile Arcellx Alternatives Marker Therapeutics, Inc. Alternatives Apexigen Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at NexImmune, Inc. on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.